Abstract
Tuberculosis (TB) remains an important public health problem. Of great concern is the increase in number of drug-resistant TB and the reduced therapeutic option for its treatment. In Brazil, in 2018, 1,119 patients with TB resistant to rifampicin (TBRR) or to rifampicin and isoniazid (TBMR) were notified. Of the total number of cases reported as TBRR/MR, only 141 (12.6%) were tested for s…